Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Entera bio ltd. symbols : Amgn save search
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
Published: 2023-02-15 (Crawled : 15:20) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 2.34%
H: 9.2%
C: 8.45%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.34%
H: 0.14%
C: -0.06%
eb613 treatment meeting review osteoporosis
Entera Bio to Participate in the SVB Securities Global Biopharma Conference
Published: 2023-02-13 (Crawled : 15:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: -2.2%
H: 4.49%
C: 1.11%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.29%
H: 0.26%
C: 0.19%
biopharma global conference
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis- Total Hip BMD Established as Primary Endpoint -
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
Published: 2022-09-21 (Crawled : 13:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 0.0%
H: 7.73%
C: 6.61%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.62%
H: 0.65%
C: -2.04%
eb613 treatment impact potential osteoporosis
Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
Published: 2022-09-12 (Crawled : 21:00) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 0.71%
H: 0.72%
C: -1.42%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.25%
H: 0.05%
C: -4.29%
global conference
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
Published: 2022-09-12 (Crawled : 11:00) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 0.72%
H: 6.43%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
eb613 correlation meeting response study osteoporosis
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting
Published: 2022-07-26 (Crawled : 12:20) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 4.55%
H: 2.72%
C: 2.17%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.37%
H: 1.66%
C: 0.6%
meeting presentation
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities
Published: 2022-06-17 (Crawled : 04:20) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: -4.09%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
research
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
Published: 2022-05-12 (Crawled : 13:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: -11.83%
H: 14.78%
C: 10.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.46%
H: 1.99%
C: 1.94%
results
Entera Bio to Report First Quarter 2022 Financial Results on May 12
Published: 2022-04-28 (Crawled : 15:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: -1.73%
H: 2.74%
C: 0.78%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -5.25%
H: 3.05%
C: 1.02%
report results
Entera Bio Reports Financial Results for the Year Ended December 31, 2021
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 0.45%
H: 0.67%
C: -4.44%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
financial results report results
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
Published: 2022-03-03 (Crawled : 15:00) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: -3.79%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 2.3%
H: 0.0%
C: 0.0%
financial results report results
Entera Bio to Present at Aegis Virtual Conference on February 23rd
Published: 2022-02-17 (Crawled : 19:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: -1.41%
H: 2.14%
C: -0.48%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.53%
H: 0.82%
C: 0.09%
conference
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 613
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
Entera Bio Reports Third Quarter 2021 Financial Results
Published: 2021-11-10 (Crawled : 14:00) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 1.02%
H: 3.28%
C: -4.29%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
financial results results
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
Published: 2021-10-28 (Crawled : 14:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 1.49%
H: 6.1%
C: 3.9%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.25%
H: 1.16%
C: 0.04%
drug technology liver
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
Published: 2021-10-06 (Crawled : 14:00) - biospace.com/
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 0.44%
H: 2.39%
C: -2.61%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.25%
H: 0.36%
C: -0.63%
phase 2 bone positive conference
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ENTX | $2.25 1.35% 1.33% 170K
|
Health Technology
|
| O: 0.82%
H: 5.26%
C: 4.88%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.01%
H: 0.25%
C: -0.98%
presentation phase 2 osteoporosis eb613
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.